Inhibitory effects of the peptide (CKPV)2 on endotoxin-induced host reactions.
Gatti. Stefano S; Carlin. Andrea A; Sordi. Andrea A; Leonardi. Patrizia P; Colombo. Gualtiero G; Fassati. Luigi R LR; Lipton. James M JM; Catania. Anna A
Key Findings
- (CKPV)2 reduced TNF‑alpha production in LPS‑stimulated human PBMCs, matching a known anti‑inflammatory peptide and outperforming the single KPV unit
- In rats, (CKPV)2 markedly lowered the surge of circulating TNF‑alpha after an LPS injection
- During LPS‑induced peritonitis, (CKPV)2 restored normal net ultrafiltrate and significantly lowered TNF‑alpha and nitrite levels in blood and peritoneal fluid
Practical Outcomes
- The peptide shows promising anti‑inflammatory power in early experiments, suggesting it could become a therapeutic for inflammatory conditions. However, because it’s only been tested in cells and animals, there’s no safe dosage or protocol for self‑administration yet. Keep an eye on future clinical trials before considering it for personal health regimens.
Summary
The dimer peptide (CKPV)2, made of two short KPV sequences, was shown to strongly cut down inflammation markers like TNF‑alpha in lab‑grown human immune cells and in rats given a bacterial toxin. It also helped keep fluid balance normal in a rat model of peritonitis. While these results point to a powerful anti‑inflammatory effect, the work is still at the cell‑culture and animal‑testing stage, so it isn’t ready for personal use yet.
Abstract
alpha-Melanocyte stimulating hormone (alpha-MSH) is an endogenous peptide that has remarkable anti-inflammatory and antimicrobial effects. These activities have been traced to the C-terminal tripeptide Lys-Pro-Val (KPV). A dimer composed of two KPV sequences connected with a Cys-Cys linker, (CKPV)2, is currently under clinical investigation for antimicrobial use. The present research was designed to evaluate effects of (CKPV)(2) on endotoxin-induced host reactions in vitro and in vivo. Effects of (CKPV)2, KPV, and [Nle4-dPhe7]-alpha-MSH (NDP-alpha-MSH) on tumor necrosis factor alpha (TNF-alpha) production were determined: 1) in human peripheral blood mononuclear cells (PBMC) stimulated with lipopolysaccharide (LPS) in vitro, and 2) in rats injected with LPS i.v. and sacrificed at 1 h. In additional experiments, dialysis peritonitis was induced in rats by adding LPS to dialysis fluid. Net ultrafiltrate was calculated and concentrations of nitrite (NO2-) and TNF-alpha were measured in blood and peritoneal fluid at 7 h. (CKPV)2 inhibited TNF-alpha production by LPS-stimulated human PBMC. This small peptide was as effective as NDP-alpha-MSH and more potent than KPV. Similar effectiveness was observed in vivo: 1 h after LPS injection, the large increase in circulating TNF-alpha was markedly reduced by (CKPV)2 treatment. In LPS-induced peritonitis, (CKPV)2 restored net ultrafiltrate to control values and significantly inhibited concentrations of TNF-alpha and NO2- both in plasma and in dialysate. The remarkable capacity of (CKPV)2 to inhibit endotoxin-induced host reactions suggests that it may be useful in treatment of inflammatory disorders.
Study Information
pubmed
2006
2006-01-18T00:00:00.000Z
10.1016/j.jss.2005.08.009